Clinical Trial Update: Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD [Phase 2]

View source ↗

Summary

This phase 2 study reports the efficacy and safety of a 4-week inhaled BI 1744 CL treatment in Japanese patients with chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BI 1744 CL

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2014-06-10